Option chain shows key data for NeOnc Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NeOnc Technologies.

NeOnc Technologies (NASDAQ:NTHI) Stock, Option Chain

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").

Display,Of,Stock,Market,Quotes

Earnings

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

AGRI

BCTX

BTOG

ENPH

ETNB

FRGE

GAIA

GELS

MRIN

NDRA

NTHI

PEGA

SEDG

SNOA

SXTC

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

The Robinhood Trade

$BTC

ARHS

BASE

CAPR

CDNA

GATE

HOOD

IIPR

INNV

KULR

RGTI

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.

Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Stock Movers

CTOR

DGLY

HLMN

ICCT

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Holdings Inc

Management

Press Releases

NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors

NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market

General

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Health Care

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies

Omeros

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Pliant Therapeutics

scPharmaceuticals

Septerna

SNDL

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tvardi Therapeutics

Ventyx Biosciences

Comments

NeOnc Technologies

NeOnc Technologies (NTHI) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell